Visia Imaging has agreed to give Bio-Rad Laboratories commercialization rights to its second-generation immunofluorescence slide processing and reading platform designed to evaluate autoimmune diseases. The technology, which will be offered together with the BioPlex 2200 System, will give Bio-Rad the capacity to provide autoimmune laboratories a more comprehensive range of automation solutions; the companies did not disclose terms of the deal.
Visia Imaging reaches commercialization deal with Bio-Rad
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.